Elucidating therapeutic potential of melatonin signaling in type 2 diabetes

Loss or inadequate stimulation of melatonin signaling is associated with development of type 2 diabetes mellitus and beta cell dysfunction in humans. However, mechanisms underlying this association are unknown. Dr. Matveyenko's lab is examining molecular pathways activated by melatonin signaling in beta cells, and whether enhanced activation of beta cell melatonin signaling may provide novel therapeutic options to treat type 2 diabetes mellitus.